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T
he diagnosis of dementia is a complicated enterprise. This is partly caused by the insidious
onset of most diseases that cause dementia. The difficulty is clearly captured in the question:
‘‘Where does ageing stop and dementia begin?’’. The availability of symptomatic treatment
(for example, acetyl cholinesterase inhibitors) and the development of new disease modifying
drugs emphasises the need for improved diagnostic accuracy. Patients that are in the earliest
stages of the disease may potentially profit most from disease modifying drugs. This further
underlines the importance of a correct clinical diagnosis early in the course of the disease. During
lifetime, with careful evaluation and the application of well defined, clinical criteria, ‘‘probable’’
diagnoses can be made with a relatively high level of accuracy. A definite diagnosis of Alzheimer’s
disease (AD) or most other diseases that cause dementia can only be made post mortem, after
necropsy.
Neuropathology accumulates gradually, and it has been shown that neuropathological features,
eventually leading to the clinical syndrome of dementia, may be present as early as 20 years
before the first symptoms become overt. Therefore, based on clinical criteria alone, the diagnosis
cannot be made until the disease is in a relatively far advanced stage. There is a clear need for
sensitive and reliable biologic markers that are able to demonstrate the presence of
neuropathology before a patient has reached the stage of clinical dementia. Although as yet there
are no biomarkers that can diagnose AD or most other dementias with certainty, neuroimaging
and laboratory markers may add positive evidence for the presence of neuropathology.
In this article, an overview will be given of the possibilities of diagnosing dementia. The first
part consists of a short description of the general diagnostic work-up of dementia. Due to the
general character of this overview, we will not go into the clinical criteria of the specific diseases
that cause dementia. Rather, we will describe the general criteria for dementia as described in the
Diagnostic and statistical manual of mental disorders, 4th ed (DSM IV).1 The second part will be
dedicated to the quest for neuropathology underlying dementia, with use of laboratory and
neuroimaging investigations. Some of these investigations, like magnetic resonance imaging
(MRI), are already widely used in clinical practice, whereas others—for example, biomarkers
obtained with lumbar puncture—hold promise for the future.
CLINICAL CRITERIAc
The practice parameter of the American Academy of Neurology recommends as a guideline that
the definition of dementia according to the DSM IV (which is identical to the DSM-III-R) is
reliable, and should be used in the diagnostic work-up of dementia.1 2 According to the DSM IV,
dementia is present if an individual develops multiple cognitive deficits that cause impairment in
social or occupational functioning and represent a significant decline from a previous level of
functioning (table 1).
A deterioration of cognitive function is central to the criteria of dementia. The diagnostic work-
up of dementia should therefore always begin by careful history taking in interviews with both
the patient and a reliable informant. Can the patient and the informant describe the character,
development, and progression of the cognitive complaints? Can they give examples? In this
respect, it is important to remember that a cognitive complaint is not by definition the same as a
cognitive deficit. For example, when a patient describes his or her memory problems in detail (an
appointment X with person Y was forgotten on date Z), this provides a clue that the memory for
the problems may still be good enough. Although the patient presents with a complaint, this does
not necessarily reflect a formal deficit. In a cohort of 1000 consecutive patients referred to a
memory clinic because of cognitive complaints, 29% of patients had no demonstrable cognitive
deficits.3 Dementia was diagnosed in 43%. Finally, 28% of patients suffered isolated amnesia,
other or uncertain cognitive deficits, or could not be classified.
The concept of mild cognitive impairment (MCI) refers to the transitional phase between
normal and dementia.4 Typically, patients suffer from an isolated memory impairment, with
global cognitive function still relatively intact (amnestic MCI). The concept of MCI has been
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broadened to include patients with isolated impairment of
another cognitive function than memory (non-amnestic
MCI), and with mild impairment of multiple cognitive
functions (multi-domain MCI). Patients with MCI are at an
increased risk of developing dementia. Approximately 15% of
MCI patients progress to dementia (mostly AD) per year, as
compared with 1–2% of the normal population. Although at
an increased risk, not all patients with MCI develop
dementia. Some MCI patients suffer incipient AD, whereas
others have a benign form of cognitive deficits that will not
progress.
In AD, memory deficits are often the first and most salient
symptoms. However, occasionally, AD may also present with
agnosia, apraxia and aphasia being more prominent than
memory deficits. Moreover, other types of dementia typically
present with other profiles of cognitive dysfunction. For
example, vascular dementia (VaD) is characterised by mental
slowness and executive dysfunctioning. Patients with fronto-
temporal lobar degeneration (FTLD) suffer primarily from
executive dysfunctioning and/or aphasia. Moreover, beha-
vioural problems may precede cognitive deficits by years. In
addition to the interview with the patient and informant,
observation of a patient is of the utmost importance. Is the
patient able to relate his problems in a coherent way? If not,
this may suggest aphasia. Does the patient behave in a
‘‘clumsy’’ manner when asked to put on reading glasses, or
when asked to undress for the physical examination?
Clumsiness may be a sign of apraxia. To get a first impression
of general cognitive functioning, testing of mental status may
prove valuable. Simple questions and tasks such as those of
the mini mental state examination (MMSE) provide insight
into the level of cognitive functioning of a patient (fig 1). The
MMSE has a maximum score of 30. Scores below 25 are
considered as congruent with a diagnosis of dementia. With a
high level of education, a higher score may already be
suggestive of cognitive dysfunction, while a score below 25 is
by no means synonymous with dementia. The clock drawing
test, in which a patient is asked to draw a clock and set the
time for 10 after 11 can give an impression of visuospatial
and executive functioning (fig 2). If the history and cognitive
screening tests do not establish the diagnosis, referral to a
neuropsychologist to provide a more detailed evaluation of
memory and other cognitive functions is appropriate.
The standard diagnostic work-up of dementia should also
include a general neurological and physical examination,
assessment of behavioural disturbances, and laboratory
screening. The aims of laboratory investigations include (1)
to identify co-morbidity and/or complications; (2) to reveal
potential risk factors; (3) to explore the background of
frequently associated confusional states; and (4) more rarely
to identify the primary cause of dementia. The following
blood tests are generally proposed for all patients at first
evaluation: blood sedimentation rate; complete blood cell
count; electrolytes; glucose; renal and liver function tests,
Table 1 DSM IV criteria for dementia1
(A) Development of multiple cognitive deficits manifested by both:
1. Memory impairment (impaired ability to learn new information or to
recall previously learned information)
2. One (or more) of the following cognitive disturbances:
– aphasia (language disturbances)
– apraxia (impaired ability to carry out motor activities despite intact
motor function)
– agnosia (failure to recognise or identify objects despite intact
sensory function)
– disturbance in executive functioning (that is, planning, organising,
sequencing, abstracting)
(B) Cognitive deficits in criteria A1 and A2 each cause significant
impairment in social or occupational functioning and represent a
significant decline from a previous level of functioning
(C) Deficits do not occur solely during a delirium
(D) Deficits not due to psychiatric disease (major depression,
schizophrenia)
Figure 1 Example and copies of the interlocking pentagons from the
mini mental state examination by patients with Alzheimer’s disease (AD).
Figure 2 Clock drawings by patients with AD. In the clock drawing
test, the patient is asked to draw a clock and set the time for 10 after 11.
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thyroid stimulating hormone, serological test for syphilis,
detection of B12. Assessment of co-morbidities is essential for
the diagnosis and management of dementia. Treatable co-
morbidities that are commonly observed in the elderly, and in
patients with suspected dementia in particular, include
depression, B12 deficiency, and hypothyroidism.2 Although
treatment of these disorders may not completely reverse
cognitive dysfunction, they should be recognised and treated.
Based on clinical criteria alone, the diagnosis of dementia
cannot be made until a relatively far advanced disease stage,
as gradually accumulating neuropathology may be present
many years before symptoms become clinically overt. With
continuing attention of the media and public awareness for
the growing public health problem resulting from dementia,
patients tend to seek help in ever earlier stages. This poses the
physician a problem, as clinical criteria are lacking in
sensitivity in the earliest stages of disease. In response to
the demand for reliable prognoses in the earliest stages of
disease, diagnostic procedures turn from an exclusionary to
an inclusionary approach. Traditionally, additional investiga-
tions were performed to rule out other potential causes of
cognitive decline. Recent developments are resulting in the
use of laboratory and neuroimaging investigations to seek
positive evidence for the diagnosis of AD or other forms of
dementia. Modern biomarkers aim to provide more direct
evidence for the presence or absence of neuropathology,
enabling meaningful prognoses and possible intervention in
early disease stages. The following is an overview of currently
used laboratory and imaging techniques. Some of these are
already used in the standard diagnostic work-up of dementia,
while others are still in an experimental stage.
MAGNETIC RESONANCE IMAGING
In the recent practice parameter on the diagnosis of
dementia, structural neuroimaging in the routine initial
evaluation of patients with dementia is recommended as a
guideline.2 The traditional view has been that computed
tomography and magnetic resonance imaging (MRI) are
performed to exclude other abnormalities that are potentially
amenable to surgical treatment, such as a tumour (fig 3),
haematoma, or hydrocephalus. In a memory clinic setting,
such potentially reversible conditions detected by imaging
appear to underlie about 4% of dementias.3 In addition to
exclusion of gross structural pathology, imaging is increas-
ingly being used to add positive or negative predictive value
in the diagnosis of the more common dementing illnesses.5
Medial temporal lobe
Neuropathological studies have implicated the medial tem-
poral lobe—including the hippocampus, amygdala, parahip-
pocampal gyrus, and entorhinal cortex—as an early site of
pathological involvement in AD, and consequently many
imaging studies have focused on this part of the brain.6
Hippocampal volume loss on MRI has been shown to predict
subsequent fulfilment of neuropathological criteria of AD.7
Hippocampal volumes have been shown to be reduced in
AD patients when compared to controls (fig 4).8 However,
this finding is not specific for AD, as hippocampal atrophy
also occurs in other common dementias such as VaD,
dementia with Lewy bodies (DLB), and FTLD. It is an
unresolved issue as to whether different types of neuro-
pathology—associated with the different types of dementia—
result in the same macroscopic feature of hippocampal
atrophy, or if the hippocampal volume loss observed in
different types of dementia reflects an overlap of neuro-
pathology between dementias. Hippocampal atrophy is a
relatively early marker of pathology. In patients with MCI, it
has been shown to be predictive of progression to dementia,
mostly AD.9 Moreover, hippocampal volume loss has been
observed in asymptomatic subjects at risk of autosomal
dominant familial AD.10
Volumetric studies have shown that structures in the
medial temporal lobe are specifically involved in neuro-
degenerative disease. However, due to the time intensive
nature of the measurement, volumetry of the hippocampus is
not easily employed in routine clinical practice. Visual rating
scales, although cruder estimates of atrophy, can provide
valuable tools that are more easily applicable in clinical
practice. A widely used five point visual rating scale evaluates
the width of the choroid fissure, the width of the temporal
horn, and the height of the hippocampus (table 2).11
Sensitivity and specificity for detection of mild to moderate
AD compared with controls based on the presence of atrophy
of the medial temporal lobe is 85% and 88%, respectively.5
Specific pattern of atrophy
Atrophy of the medial temporal lobe is suggestive of AD,
although it does not rule out other causes of dementia. A
minority of patients with AD presents with prominent
posterior cortical atrophy on MRI. These patients are also
referred to as biparietal AD. Other specific patterns of atrophy
lower the probability of a diagnosis of AD. Frontal and
temporal atrophy have been reported as suggestive of
frontotemporal dementia (FTD), although absence of any
abnormality is not uncommon in this disorder (fig 5).12
Asymmetrical, predominantly left sided atrophy can be
observed in progressive non-fluent aphasia and semantic
dementia. Progressive non-fluent aphasia typically presents
with left sided perisylvian atrophy, whereas semantic
dementia is characterised by left sided anterior temporal
lobe atrophy.
Figure 3 Axial magnetic resonance imaging (MRI) scan of a 60 year
old woman with slowly progressive behavioural changes and memory
deficits. The scan shows a large space occupying lesion in the right
frontal lobe. The pathological diagnosis was meningeoma.
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Vascular pathology
Imaging findings of vascular pathology include ‘‘large vessel’’
(large territorial or strategical infarctions) and ‘‘small vessel’’
(lacunes and white matter hyperintensities) disease. Criteria
for VaD include definitions of dementia, vascular disease, and
a relationship between the two. Vascular disease can be
diagnosed on clinical grounds, neuroimaging, or both. The
criteria according to the National Institute of Neurological
Disorders and Stroke–Association Internationale pour la
Recherche et l’Enseignement en Neurosciences (NINDS-
AIREN) specify clinical and radiological criteria of VaD.13
The radiological criteria require that the vascular territories
involved are considered relevant for VaD. These include large
vessel strokes in the areas of the anterior cerebral artery,
posterior cerebral artery, association areas and watershed
regions, and small vessel disease. However, considerable
interobserver variability exists for the assessment of the
radiological component of the NINDS-AIREN criteria. The
use of operational definitions improves agreement, but only
among experienced observers.14
Vascular disease is not only observed on MRI in patients
with VaD, but also in patients with AD. In fact, many
pathological studies find concomitant cerebrovascular disease
in patients with definite AD.15 16 Additional vascular pathol-
ogy significantly increases the likelihood of clinical dementia,
suggesting a synergistic effect. In addition, evidence of
cerebrovascular pathology may influence the clinical man-
agement of the patient with dementia, given that cerebro-
vascular disease may be amenable to targeted interventions
potentially ameliorating disease progression.
POSITRON EMISSION TOMOGRAPHY
It is conceivable that changes in brain function precede
structural brain changes. The two main techniques that are
used to study biochemical and physiological processes are
positron emission tomography (PET) and single photon
emission computed tomography (SPECT). PET shows glucose
metabolism (using the metabolic tracer [18F]fluoro-
deoxyglucose or FDG). SPECT assesses changes in regional
blood flow and oxygen metabolism. Both methods have
reasonable to good discriminatory power in the comparison
between AD and controls (sensitivity and specificity in the
range of 85–90%).17 Typically, temporal and parietal hypo-
metabolism and hypoperfusion are observed in AD patients
relative to controls. However, because the added value of PET
and SPECT over clinical diagnosis and structural imaging is
not always clear, these investigations are not considered
essential in the initial diagnostic work-up of dementia.2 A
potential application is the early diagnosis of FTD, where a
reduction in frontotemporal blood flow may be shown, even
in the absence of evidence for frontotemporal atrophy.
An exciting novel application of PET is the in-vivo imaging
of amyloid. The amyloid b protein is considered essential to
the pathogenesis of AD, as it is the main constituent of
neuritic plaques—one of the neuropathological hallmarks of
AD. A gradual cortical deposition of amyloid b into plaques
was described by Braak and Braak, who proposed that
amyloid plaques were first deposited in the basal neocortex,
and subsequently spread to all areas of the cortex.6 Up until
now, a definite diagnosis of AD can only be made post
mortem, because the neuropathological characteristics of the
disorder—neuritic plaques and neurofibrillary tangles—can
only be observed at necropsy. If it were possible to detect
amyloid b in vivo, this would add considerably to the
potential for an early diagnosis of AD.
After years of preclinical research, several PET tracers have
been developed for this purpose, and the first results in patients
with AD are encouraging. Two compounds—fluorine-18-
labelled FDDNP ([18F]FDDNP),18 and the Pittsburgh com-
pound B (carbon-11-labelled PIB) ([11C]PIB)19—have been
studied to date, but several others are currently being
developed. [18F]FDDNP labels both neurofibrillary tangles
and b-amyloid neuritic plaques. In contrast, [11C]PIB only
labels amyloid deposits. Both tracers showed greater retention
in AD patients when compared to controls in areas known
to be affected by Alzheimer pathology. In addition, a
negative correlation was observed between binding of
FDDNP and dementia severity. PIB did not show any
significant correlation between amyloid load and cognitive
function of the AD patients. From neuropathological
Figure 4 Coronal MRI scan shows
absence (left) and presence (right) of
atrophy of the medial temporal lobe in a
healthy elderly subject and a patient
with AD.
Table 2 Visual assessment of medial temporal lobe
atrophy
Score
Width of choroid
fissure
Width of temporal
horn
Height of
hippocampus
0 Normal Normal Normal
1 q Normal Normal
2 qq q QQ
3 qqq qq QQ
4 qqq qqq QQQ
qincreased; Qdecreased. Reproduced with permission of BMJ
Publishing Group.11
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studies, it is known that cognitive decline is associated
with the progression of neurofibrillary tangles, rather than
with the spread of neuritic plaques. This may explain the
observation of an association between cognitive function
and FDDNP (that seems to label both neurofibrillary
tangles and amyloid containing neuritic plaques), but not
between cognitive function and PIB (that seems to label
amyloid deposition only).
For both tracers, many methodological issues still need to
be resolved and the clinical value of in vivo amyloid imaging
remains to be established. However, direct imaging of
neuritic plaques, and hopefully also neurofibrillary tangles,
is an exciting development that holds promise for the future.
In vivo amyloid imaging may considerably add to our
understanding of the underlying pathophysiological mechan-
isms of AD and could prove valuable as a surrogate marker in
studies of anti-amyloid drugs.
ELECTROENCEPHALOGRAPHY
Generalised slowing of the background rhythm on electro-
encephalography (EEG) is a frequent finding in AD and DLB,
and may be helpful in distinguishing such patients from
those with depression. The described EEG changes are not
specific for AD, and can also be found in other diffuse
neuroencephalopathies. In FTLD, the EEG may be normal
until a far advanced disease stage. EEG seems unable to
distinguish MCI patients from controls, nor to discriminate
stable MCI patients from those who will convert to AD.20
However, it has been suggested that EEG abnormalities in AD
are suggestive of a faster progression of disease.21
The EEG may be a useful adjunct when there is diagnostic
doubt. An abnormal EEG substantially raises the a priori
chance of AD, whereas a normal EEG has relatively little
meaning. The observation of periodic sharp wave complexes
is specific for Creutzfeld-Jakob disease (CJD), particularly the
sporadic form. The sensitivity and specificity associated with
the presence of these findings were 66% and 74%, respec-
tively.22 Epilepsy is a relatively rare cause of memory deficits.
Transient epileptic amnesia caused by focal temporal lobe
seizure activity can masquerade as AD. Even in patients that
have no outward clinical manifestations of epilepsy, epilepti-
form abnormalities on EEG may have diagnostic importance.
GENETIC TESTING
Only a small proportion of all individuals with dementia
suffer from a familial form, caused by an autosomal
dominant mutation. There are a few types of dementia that
are uniquely autosomal dominantly inherited, such as
Huntington’s disease and cerebral autosomal dominant
arteriopathy with subcortical infarcts and leucoencephalo-
pathy (CADASIL). Genetic testing for these diseases in
specialised centres results in high sensitivity and specificity.
By contrast, the largest proportion of patients suffering from
the most widespread forms of dementia, such as AD, VaD,
DLB, and FTLD, are ‘‘sporadic’’. In a minority of these
patients, these types of dementia occur as autosomal
dominant these types of disorders, with similar clinical
presentation, although often with an earlier age of onset.
Mutations in several genes (including Ab precursor protein,
presenilin 1, and presenilin 2) have been shown to cause AD,
but these account for less than 5% of all cases. Tau mutations
are found in some cases of familial FTLD and mutations in
the prion protein gene are observed in familial CJD. The yield
from mutation screening in unselected populations is
exceedingly low. Genetic testing is thus not recommended
unless a patient presents with an appropriate phenotype and
a significant family history.
Genetic risk factors may also play a role in the so-called
sporadic cases of dementia. In AD, the apoliprotein E (APOE)
e4 polymorphism operates as a genetic risk modifier for AD.23
The presence of the APOE e4 isoform slightly increased the
positive predictive value of the AD diagnosis.24 Relative to the
neuropathological diagnosis of AD, the sensitivity of the
clinical diagnosis was 92%, whereas the sensitivity of having
at least one APOE e4 was only 65%. However, in patients with
clinical diagnoses of AD, the addition of APOE testing
increased the positive predictive value of a neuropathological
diagnosis of AD from 90% to 94% if at least one APOE e4
allele was present. In patients with a clinical diagnosis of
non-AD, the absence of an APOE e4 allele increased the
Figure 5 Axial MRI scans showing abnormalities in the spectrum of frontal temporal lobar degeneration. Frontotemporal dementia is associated with
frontal and temporal atrophy. Progressive non-fluent aphasia typically presents with left sided perisylvian atrophy, whereas semantic dementia is
characterised by left sided anterior temporal lobe atrophy.
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negative predictive value from 64% to 72%. Because of the
relatively limited gain in diagnostic accuracy, routine use of
APOE genotyping is currently not recommended in the
diagnostic evaluation of dementia.2
CEREBROSPINAL FLUID
The blood–brain barrier restricts the flow of proteins to and
from the brain, rendering biomarkers based on blood samples
relatively unfit as measures of neurodegenerative disease. In
contrast, cerebrospinal fluid (CSF) is in direct contact with
the brain. CSF provides a ‘‘window to the brain’’ as
biochemical changes resulting from pathological processes
of the brain are reflected in it. Senile plaques and
neurofibrillary tangles are the neuropathological hallmarks
of AD. Neuritic plaques are caused by extracellular aggrega-
tion of b amyloid (Ab) protein, and neurofibrillary tangles
result from hyperphosphorylation of the protein tau. CSF 42
amino acid variant of Ab (Ab42), total tau, and different
epitopes of phospho-tau (ptau) are the most frequently used
biomarkers of AD. For confirming the diagnosis of sporadic
CJD, the 14-3-3 protein is useful.
Ab42
In patients with AD, a decrease in CSF concentration of Ab42
to about 50% of that in control subjects has been observed.
The decrease in concentrations of CSF Ab42 in AD probably
reflects deposition of the protein in plaques, as low
concentrations of CSF Ab42 were found to be associated
with high numbers of plaques in the neocortex and
hippocampus.25 With specificity at 90%, the mean sensitivity
of CSF Ab42 is 86% when comparing AD with normal
ageing.26 In the differential diagnosis between AD and other
dementia disorders, CSF Ab42 is only moderately specific, as
mildly reduced concentrations of CSF Ab42 have also been
observed in other forms of dementia such as DLB, FTLD and
VaD.
Tau
CSF tau concentrations are about three times higher in
patients with AD than in normal ageing. Tau protein is
located in the neuronal axons. The concentration of tau
protein in the CSF probably reflects the intensity of neuronal
degeneration in chronic neurodegenerative disorders. In a
comparison between AD and controls, sensitivity seems to be
somewhat lower than that of Ab42. With the specificity set at
90%, the mean sensitivity of AD is 81%.26 Elevations of CSF
tau levels are also observed in CJD and after acute stroke.
Reports with respect to VaD and FTLD have been incon-
sistent.
Phosphorylated tau
The concentration of CSF phosphorylated tau protein (Ptau)
may be more specific for AD, as it specifically reflects the
phosphorylation state of tau and, thus, the formation of
tangles in AD. In comparison with CSF Ab42 and tau, a
considerably smaller number of studies have addressed
sensitivity and specificity of Ptau. With a specificity of 92%,
the mean sensitivity of Ptau to discriminate AD from normal
ageing is 80%, although sensitivities vary widely among
studies.26 It is important to notice that CSF Ptau may be more
specific for AD than Ab42 and total tau. High concentrations
of CSF Ptau have only been observed in AD, whereas normal
concentrations have been found in other dementia disorders
such as DLB, VaD, and FTLD.
Studies of CSF biomarkers in mild dementia or MCI have
suggested sensitivity figures comparable to those in later
stages, indicating that CSF markers may reflect disease in a
very early stage. Where CSF Ab42 and total tau differentiate
dementia in general from normal ageing, CSF Ptau will
increase the specificity of CSF biomarkers in the discrimina-
tion between AD and other dementias. The diagnostic yield
may be improved by the simultaneous measurement of two
biomarkers.
14-3-3 protein
Assessment of the 14-3-3 protein in the sporadic form of CJD
has a sensitivity and specificity well above 90%.2 False
positive results can be found in cerebral infarcts, encephalitis,
tumours, and rapidly progressive AD. For the identification of
CJD in cases with rapidly progressive dementia, assessment
of the 14-3-3 protein yields the highest diagnostic accuracy.
The study of CSF biomarkers is a relatively new field and
much work is still in progress. There is a lack of
standardisation of the CSF assays. Concentrations of CSF
markers have been found to vary among enzyme linked
immunosorbent assay (ELISA) methods and between differ-
ent centres using the same ELISA. Because of the variation in
CSF values among studies, it has not been possible as yet to
define generally applicable cut-off values for any of the CSF
markers. This issue is currently addressed, as laboratories are
compared on an international level. A second problem in the
evaluation of the clinical usefulness of CSF biomarkers is the
fact that almost all studies describe the results of CSF
analysis in selected patient samples. There are virtually no
studies that report on routine CSF analysis, which would be
necessary to evaluate the clinical value of CSF analysis in an
unbiased way. As yet, lumbar puncture is not recommended
as a requirement for the diagnosis of dementia. However,
results are promising and it is not unthinkable that, in the
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future, lumbar puncture with CSF analysis will be part of the
routine diagnostic work-up in a memory clinic.
DISCUSSION
This overview has addressed the clinical diagnosis of
dementia in general, and the potential for applying laboratory
and imaging biomarkers in the quest for the specific
neuropathology underlying dementia. Rather than giving a
summary of diagnostic guidelines which can be found in
other articles,2 we have attempted to lift the edge of the veil
to the exciting new developments that may be incorporated
in future guidelines.
The study of diagnostic markers for AD and other types of
dementia is hampered by some methodological issues. The
most important obstacle to the study of the diagnosis of AD is
the lack of a gold standard. Almost all data come from
clinical studies, with clinical diagnosis—based on careful
application of clinical criteria—as the gold standard. This
implies that the diagnostic performance of the marker under
study can never exceed the diagnostic performance of the
clinical diagnostic criteria that were used. This is especially a
problem, as the quest for new biomarkers is instigated by the
known insufficient sensitivity of clinical criteria in the
earliest stages of neurodegenerative disease. If sensitivity
and specificity are high, but below 100%, does this mean that
the new diagnostic marker is suboptimal, or does it reflect the
flaws of the clinical criteria?
A second problem relates to the gradual accumulation of
neuropathology and the insidious onset of clinical signs
and symptoms. It is known that neuropathological changes
eventually leading to dementia may start to accumulate as
early as 20–30 years before a patient has clinical dementia.
The question ‘‘where does ageing stop and dementia
begin?’’ is closely followed by the question ‘‘how early should
we diagnose?’’. Part of the control subjects in diagnostic
studies of new biomarkers may develop dementia in
later years. Thus, a finding of abnormal biomarkers in
control subjects may either imply a false negative, or it may
be a very early sign of imminent dementia. The suboptimal
sensitivity and specificity figures of biomarkers may at least
be partially due to poor selection of patient and control
groups.
Another possible source of circular evidence originates in
the multidisciplinary way the clinical diagnosis of dementia
is made. When the new biomarker under study in fact
contributes to the multidisciplinary diagnosis—or even when
the multidisciplinary team is not completely blinded to the
results of the new test—there is a risk of a self fulfilling
prophecy. Selection bias occurs if a positive result on a new
test contributes to the probability that a patient receives a
specific diagnosis.
Finally, many markers of dementia show abnormalities in
AD that are, however, not specific for AD. This raises the
question of whether the biomarker is not specific for the
disease, or the disease itself is not specific? This question has
received the most attention with respect to atrophy of the
medial temporal lobe, although the issue equally affects other
types of biomarkers. Atrophy of the medial temporal lobe is
expected in AD, as the neuropathology characteristic of AD
has been shown to originate in this region. However, atrophy
of the medial temporal lobe has also been reported in other
types of dementia, such as VaD, DLB, and FTLD. The question
is raised as to whether there is concomitant Alzheimer
pathology in patients with these other types of dementia, or
whether other types of neuropathology can also lead to
atrophy in the medial temporal lobe. Currently, there is no
definite answer for this question, although evidence accu-
mulates that considerable overlap exists between different
types of dementia. Evaluation of new biomarkers in large,
unselected samples and clinical series with neuropathological
confirmation of diagnosis is needed to shed more light on
this discussion.
In conclusion, assessment of cognitive decline is essential
to the clinical criteria of dementia, and biomarkers obtained
using laboratory and imaging investigations can provide
additional evidence for the presence of neuropathology.
Although as yet there is no biomarker that can diagnose
AD or any of the other major types of dementia with
certainty, progress is being made and there are some
promising new candidates for the detection of neuropathol-
ogy.
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